financetom
Business
financetom
/
Business
/
Market Chatter: UBS May Face $25 Billion Capital Requirement Under Swiss Plan
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: UBS May Face $25 Billion Capital Requirement Under Swiss Plan
May 26, 2025 10:45 AM

07:07 AM EDT, 05/20/2025 (MT Newswires) -- UBS Group ( UBS ) is expected to lose its initial bid to ease a Swiss proposal requiring higher capital reserves for foreign subsidiaries, Bloomberg reported Tuesday, citing sources familiar with the matter.

A draft law due on June 6 would require UBS to fully back losses at its overseas units, increasing coverage from 60% to 100%, the report said.

The requirement is part of a broader post-Credit Suisse overhaul that could add as much as $25 billion in capital needs for UBS, the report added.

Despite lobbying efforts from UBS and CEO Sergio Ermotti, regulators and the Swiss Federal Council are pushing for stricter rules, the news outlet reported.

A finalized bill is expected next year, with debates and votes likely concluding by 2027, while a potential public referendum could delay implementation until 2029, the report said.

UBS declined MT Newswires' request for comment, while the Swiss government did not immediately respond.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
 Lyra Therapeutics Q3 net loss narrows
 Lyra Therapeutics Q3 net loss narrows
Nov 12, 2025
Overview * Lyra reports Q3 2025 net loss of $6.0 mln, down from $11.9 mln last year * Company plans new Phase 3 trial for LYR-210, aiming for NDA submission * Cash reserves expected to fund operations into Q3 2026 Outlook * Lyra plans new Phase 3 trial for LYR-210, targeting NDA submission * Company anticipates cash reserves to fund...
What's Going On With MicroVision Shares Wednesday?
What's Going On With MicroVision Shares Wednesday?
Nov 12, 2025
MicroVision, Inc. ( MVIS ) shares are trading lower Wednesday after the company reported mixed third quarter financial results on Tuesday after the market closed. What To Know: MicroVision ( MVIS ) reported a loss of 5 cents per share, beating the consensus estimate of a 7 cent-loss. In addition, the company reported sales of $241,000, missing the consensus estimate...
Fintech firm DLocal Q3 revenue tops analyst expectations helped by higher payment volumes
Fintech firm DLocal Q3 revenue tops analyst expectations helped by higher payment volumes
Nov 12, 2025
Overview * DLocal ( DLO ) Q3 revenue grows 52% yr/yr, beating analyst expectations * Adjusted EBITDA for Q3 beats consensus, rising 37% yr/yr * Net income for Q3 rises 93% yr/yr, reflecting strong growth Outlook * Dlocal ( DLO ) did not provide specific future guidance in the statement Result Drivers * TPV GROWTH - Record TPV of US$10.4...
AN2 Therapeutics Q3 net loss narrows to $9.4 mln
AN2 Therapeutics Q3 net loss narrows to $9.4 mln
Nov 12, 2025
Overview * AN2 Therapeutics ( ANTX ) reports Q3 net loss of $9.4 mln, improved from $12.7 mln last year * Company's R&D expenses decreased to $7 mln from $8.3 mln in Q3 2024 * AN2 advances Phase 1 trial for Chagas disease, collaborates with GSK on TB research Outlook * AN2 expects to initiate Phase 2 Chagas disease study...
Copyright 2023-2026 - www.financetom.com All Rights Reserved